133 related articles for article (PubMed ID: 34449314)
1. Bioelectrical impedance analysis-based nomogram construction for predicting secondary loss of response to infliximab in bio-naïve Crohn's disease patients.
Yueying C; Jing F; Tian Y; Yuqi Q; Jun S
Biomed Pharmacother; 2021 Oct; 142():112076. PubMed ID: 34449314
[TBL] [Abstract][Full Text] [Related]
2. Are Radiomic Spleen Features Useful for Assessing the Response to Infliximab in Patients With Crohn's Disease? A Multicenter Study.
Tang CT; Yin F; Yin Y; Liu Z; Long S; Zeng CY; Chen Y; Chen YX
Clin Transl Gastroenterol; 2024 May; 15(5):e00693. PubMed ID: 38407213
[TBL] [Abstract][Full Text] [Related]
3. A Novel Radiomics Nomogram for the Prediction of Secondary Loss of Response to Infliximab in Crohn's Disease.
Chen Y; Li H; Feng J; Suo S; Feng Q; Shen J
J Inflamm Res; 2021; 14():2731-2740. PubMed ID: 34194236
[TBL] [Abstract][Full Text] [Related]
4. Infliximab response associates with radiologic findings in bio-naïve Crohn's disease.
Yueying C; Jing F; Qi F; Jun S
Eur Radiol; 2023 Aug; 33(8):5247-5257. PubMed ID: 36928565
[TBL] [Abstract][Full Text] [Related]
5. CT-based pancreatic radiomics predicts secondary loss of response to infliximab in biologically naïve patients with Crohn's disease.
Yang T; Feng J; Yao R; Feng Q; Shen J
Insights Imaging; 2024 Mar; 15(1):69. PubMed ID: 38472447
[TBL] [Abstract][Full Text] [Related]
6. A novel clinical radiomics nomogram at baseline to predict mucosal healing in Crohn's disease patients treated with infliximab.
Zhu C; Hu J; Wang X; Li C; Gao Y; Li J; Ge Y; Wu X
Eur Radiol; 2022 Oct; 32(10):6628-6636. PubMed ID: 35857074
[TBL] [Abstract][Full Text] [Related]
7. A Matrix-based Model Predicts Primary Response to Infliximab in Crohn's Disease.
Billiet T; Papamichael K; de Bruyn M; Verstockt B; Cleynen I; Princen F; Singh S; Ferrante M; Van Assche G; Vermeire S
J Crohns Colitis; 2015 Dec; 9(12):1120-6. PubMed ID: 26351386
[TBL] [Abstract][Full Text] [Related]
8. Validation of endoscopic activity scores in patients with Crohn's disease based on a post hoc analysis of data from SONIC.
Ferrante M; Colombel JF; Sandborn WJ; Reinisch W; Mantzaris GJ; Kornbluth A; Rachmilewitz D; Lichtiger S; D'Haens GR; van der Woude CJ; Danese S; Diamond RH; Oortwijn AF; Tang KL; Miller M; Cornillie F; Rutgeerts PJ;
Gastroenterology; 2013 Nov; 145(5):978-986.e5. PubMed ID: 23954314
[TBL] [Abstract][Full Text] [Related]
9. Nomogram to predict primary non-response to infliximab in patients with Crohn's disease: a multicenter study.
Ye XQ; Cai J; Yu Q; Cao XC; Chen Y; Rao MX; Chen BL; He Y; Zeng ZR; Chen H; Lin YM; Cao Q; Chen MH; Zhang SH
Gastroenterol Rep (Oxf); 2021 Aug; 9(4):329-338. PubMed ID: 34567565
[TBL] [Abstract][Full Text] [Related]
10. Development of a clinical model to predict secondary non-response of infliximab treatment in Crohn's disease.
Xu L; Shen J; Zheng Q
Int J Colorectal Dis; 2020 Nov; 35(11):2019-2026. PubMed ID: 32577870
[TBL] [Abstract][Full Text] [Related]
11. A Novel Model Based on Serum Biomarkers to Predict Primary Non-Response to Infliximab in Crohn's Disease.
Li L; Chen R; Zhang Y; Zhou G; Chen B; Zeng Z; Chen M; Zhang S
Front Immunol; 2021; 12():646673. PubMed ID: 34367126
[TBL] [Abstract][Full Text] [Related]
12. MRI-Based Radiomic Signature Identifying Secondary Loss of Response to Infliximab in Crohn's Disease.
Feng J; Feng Q; Chen Y; Yang T; Cheng S; Qiao Y; Shen J
Front Nutr; 2021; 8():773040. PubMed ID: 35047543
[TBL] [Abstract][Full Text] [Related]
13. Visceral Fat Is Associated With Mucosal Healing of Infliximab Treatment in Crohn's Disease.
Shen W; Cao L; Li Y; Cai X; Ge Y; Zhu W
Dis Colon Rectum; 2018 Jun; 61(6):706-712. PubMed ID: 29722729
[TBL] [Abstract][Full Text] [Related]
14. Nutritional status and bioelectrical phase angle assessment in adult Crohn disease patients receiving anti-TNFα therapy.
Emerenziani S; Biancone L; Guarino MPL; Balestrieri P; Stasi E; Ribolsi M; Rescio MP; Altomare A; Cocca S; Pallone F; Cicala M
Dig Liver Dis; 2017 May; 49(5):495-499. PubMed ID: 28096060
[TBL] [Abstract][Full Text] [Related]
15. Development and validation of a clinical radiomics nomogram to predict secondary loss of response to infliximab in Crohn's disease patients.
Zhu C; Wang X; Wang S; Hu J; Gao Y; Li C; Li J; Wu X
Heliyon; 2023 Apr; 9(4):e14594. PubMed ID: 37151630
[TBL] [Abstract][Full Text] [Related]
16. A random forest model predicts responses to infliximab in Crohn's disease based on clinical and serological parameters.
Li Y; Pan J; Zhou N; Fu D; Lian G; Yi J; Peng Y; Liu X
Scand J Gastroenterol; 2021 Sep; 56(9):1030-1039. PubMed ID: 34304688
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of Infliximab Therapy and Predictors of Response in Korean Patients with Crohn's Disease: A Nationwide, Multicenter Study.
Choi CH; Song ID; Kim YH; Koo JS; Kim YS; Kim JS; Kim N; Kim ES; Kim JH; Kim JW; Kim TO; Kim HS; Kim HJ; Park YS; Park DI; Park SJ; Song HJ; Shin SJ; Yang SK; Ye BD; Lee KM; Lee BI; Lee SY; Lee CK; Im JP; Jang BI; Jeon TJ; Cho YK; Chang SK; Jeon SR; Jung SA; Jeen YT; Cha JM; Han DS; Kim WH;
Yonsei Med J; 2016 Nov; 57(6):1376-85. PubMed ID: 27593865
[TBL] [Abstract][Full Text] [Related]
18. Development and Validation of an Interleukin-6 Nomogram to Predict Primary Non-response to Infliximab in Crohn's Disease Patients.
Chen Y; Li H; Feng Q; Shen J
Front Pharmacol; 2021; 12():654985. PubMed ID: 33986682
[No Abstract] [Full Text] [Related]
19. Differential diagnosis of Crohn's disease and intestinal tuberculosis: development and assessment of a nomogram prediction model.
Zeng S; Lin Y; Guo J; Chen X; Liang Q; Zhai X; Tao J
BMC Gastroenterol; 2022 Nov; 22(1):461. PubMed ID: 36384447
[TBL] [Abstract][Full Text] [Related]
20. Relationship of Body Mass Index to Clinical Outcomes after Infliximab Therapy in Patients with Crohn's Disease.
Brown P; Clark T; Dowson G; Warren L; Hamlin J; Hull M; Subramanian V
J Crohns Colitis; 2016 Oct; 10(10):1144-50. PubMed ID: 26995185
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
